GlassScriptPhysician profile
Neil Keshvani
NPI 1003279969
$6,365.86
in general payments reported to CMS, 2019-2025
11 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2023: $164 · 2024: $5,756 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,355 · Food and Beverage: $715 · Travel and Lodging: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,355.00 |
| Food and Beverage | $714.71 |
| Travel and Lodging | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $5,438.99 | 2024 | Tryvio |
| Abbott Laboratories | $212.16 | 2021 | |
| Roche Diabetes Care, INC. | $141.03 | 2024 | |
| Novo Nordisk INC | $123.65 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.59 | 2025 | |
| American Regent | $103.16 | 2024-2025 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.30 | 2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $50.98 | 2025 | |
| Scpharmaceuticals INC. | $42.07 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.32 | 2023 | Xifaxan |
| Mindray Ds USA, INC. | $14.61 | 2023 | Te X, Te7 Max |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Keshvani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.